Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nasopharyngeal Neoplasms | 1 | 2017 | 278 | 0.520 |
Why?
|
High-Throughput Nucleotide Sequencing | 7 | 2022 | 3698 | 0.440 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2017 | 558 | 0.410 |
Why?
|
Mutation | 13 | 2022 | 29491 | 0.380 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2022 | 4955 | 0.360 |
Why?
|
Lung Neoplasms | 12 | 2022 | 12608 | 0.340 |
Why?
|
NF-kappa B | 1 | 2017 | 2584 | 0.330 |
Why?
|
Lymphatic Metastasis | 1 | 2015 | 2975 | 0.300 |
Why?
|
Peptide Elongation Factor 1 | 1 | 2006 | 42 | 0.300 |
Why?
|
Leishmania donovani | 1 | 2006 | 63 | 0.290 |
Why?
|
Carcinoma | 1 | 2017 | 2325 | 0.270 |
Why?
|
Sequence Analysis, Protein | 1 | 2006 | 261 | 0.270 |
Why?
|
Protein Kinase Inhibitors | 6 | 2022 | 5495 | 0.270 |
Why?
|
Molecular Targeted Therapy | 5 | 2021 | 2865 | 0.260 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2021 | 1671 | 0.250 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2020 | 5271 | 0.250 |
Why?
|
Models, Chemical | 1 | 2006 | 648 | 0.250 |
Why?
|
Drug Discovery | 1 | 2011 | 1071 | 0.240 |
Why?
|
Pharmaceutical Preparations | 1 | 2011 | 1030 | 0.230 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2016 | 4038 | 0.230 |
Why?
|
Sequence Alignment | 1 | 2006 | 2289 | 0.210 |
Why?
|
Models, Molecular | 3 | 2016 | 5542 | 0.210 |
Why?
|
Alkylating Agents | 1 | 2021 | 129 | 0.210 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2016 | 908 | 0.200 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1635 | 0.200 |
Why?
|
Neoplasms | 4 | 2022 | 20572 | 0.190 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2021 | 196 | 0.190 |
Why?
|
Endosomal Sorting Complexes Required for Transport | 1 | 2020 | 154 | 0.190 |
Why?
|
Vacuolar Proton-Translocating ATPases | 1 | 2020 | 192 | 0.180 |
Why?
|
Breast Neoplasms, Male | 1 | 2020 | 205 | 0.180 |
Why?
|
Arginase | 1 | 2019 | 79 | 0.180 |
Why?
|
Ribonucleoproteins | 1 | 2021 | 385 | 0.180 |
Why?
|
Computational Biology | 1 | 2011 | 3568 | 0.170 |
Why?
|
Pathology, Molecular | 1 | 2022 | 346 | 0.170 |
Why?
|
Aneuploidy | 1 | 2021 | 480 | 0.170 |
Why?
|
bcl-X Protein | 1 | 2019 | 400 | 0.170 |
Why?
|
TNF Receptor-Associated Factor 3 | 1 | 2017 | 49 | 0.160 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3100 | 0.160 |
Why?
|
Glioma | 2 | 2022 | 3299 | 0.150 |
Why?
|
Proteins | 1 | 2011 | 6166 | 0.150 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5335 | 0.140 |
Why?
|
Receptors, Mitogen | 1 | 2015 | 65 | 0.140 |
Why?
|
Cholangiocarcinoma | 1 | 2021 | 526 | 0.140 |
Why?
|
Viral Matrix Proteins | 1 | 2017 | 281 | 0.140 |
Why?
|
Bile Duct Neoplasms | 1 | 2021 | 580 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2020 | 609 | 0.140 |
Why?
|
Myeloproliferative Disorders | 1 | 2021 | 607 | 0.140 |
Why?
|
Receptor, Notch1 | 2 | 2016 | 525 | 0.130 |
Why?
|
Nuclear Proteins | 3 | 2021 | 5988 | 0.130 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2016 | 732 | 0.130 |
Why?
|
ras GTPase-Activating Proteins | 1 | 2015 | 98 | 0.130 |
Why?
|
Receptor, Notch2 | 1 | 2015 | 93 | 0.130 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2019 | 1124 | 0.130 |
Why?
|
Myeloid Cells | 1 | 2019 | 789 | 0.130 |
Why?
|
Exons | 1 | 2020 | 2480 | 0.120 |
Why?
|
Neutrophil Infiltration | 1 | 2016 | 401 | 0.120 |
Why?
|
Signal Transduction | 1 | 2017 | 23997 | 0.120 |
Why?
|
Cell Line, Tumor | 9 | 2021 | 16989 | 0.120 |
Why?
|
Serine | 1 | 2016 | 857 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2021 | 1615 | 0.110 |
Why?
|
Phenylcarbamates | 1 | 2011 | 40 | 0.110 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2021 | 8685 | 0.110 |
Why?
|
Mitogen-Activated Protein Kinase 14 | 1 | 2011 | 28 | 0.110 |
Why?
|
Tosyl Compounds | 1 | 2011 | 116 | 0.110 |
Why?
|
Colorectal Neoplasms | 2 | 2021 | 6590 | 0.100 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2021 | 1521 | 0.100 |
Why?
|
Adaptive Immunity | 1 | 2016 | 702 | 0.100 |
Why?
|
Herpesvirus 4, Human | 1 | 2017 | 1257 | 0.100 |
Why?
|
Base Sequence | 3 | 2022 | 13317 | 0.100 |
Why?
|
Transcription Factors | 3 | 2021 | 12073 | 0.100 |
Why?
|
Dendritic Cells | 1 | 2021 | 2731 | 0.100 |
Why?
|
Brain Neoplasms | 2 | 2022 | 8805 | 0.100 |
Why?
|
Databases, Protein | 1 | 2011 | 375 | 0.090 |
Why?
|
Reproducibility of Results | 2 | 2022 | 19537 | 0.090 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2016 | 3016 | 0.090 |
Why?
|
Aged, 80 and over | 9 | 2022 | 58528 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2010 | 213 | 0.090 |
Why?
|
AMP-Activated Protein Kinases | 3 | 2016 | 621 | 0.090 |
Why?
|
Humans | 31 | 2022 | 717280 | 0.090 |
Why?
|
Sequence Analysis, DNA | 2 | 2020 | 4916 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2016 | 2972 | 0.080 |
Why?
|
Genome, Human | 2 | 2020 | 4472 | 0.080 |
Why?
|
Software | 1 | 2021 | 4367 | 0.080 |
Why?
|
Aged | 13 | 2022 | 162862 | 0.070 |
Why?
|
Apoptosis | 2 | 2021 | 10119 | 0.070 |
Why?
|
Protein Binding | 2 | 2011 | 9665 | 0.070 |
Why?
|
Protein Kinase C | 1 | 2011 | 1278 | 0.070 |
Why?
|
Indoles | 2 | 2011 | 1859 | 0.070 |
Why?
|
DNA Helicases | 2 | 2021 | 827 | 0.070 |
Why?
|
Adenocarcinoma | 2 | 2015 | 6370 | 0.070 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2961 | 0.070 |
Why?
|
Genomics | 4 | 2021 | 5338 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2020 | 3697 | 0.070 |
Why?
|
Middle Aged | 13 | 2022 | 215054 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 8944 | 0.070 |
Why?
|
Gene Expression Profiling | 3 | 2016 | 9532 | 0.070 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5022 | 0.060 |
Why?
|
Papillomavirus Infections | 1 | 2015 | 1516 | 0.060 |
Why?
|
DNA Methylation | 1 | 2016 | 4102 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2019 | 4750 | 0.060 |
Why?
|
Male | 15 | 2022 | 351399 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2022 | 15600 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2016 | 2745 | 0.050 |
Why?
|
Sulfonamides | 1 | 2011 | 1932 | 0.050 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2006 | 2931 | 0.050 |
Why?
|
Species Specificity | 1 | 2006 | 2620 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2006 | 1836 | 0.050 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13754 | 0.050 |
Why?
|
Cytokines | 1 | 2016 | 7223 | 0.050 |
Why?
|
Sucrose | 1 | 2021 | 185 | 0.050 |
Why?
|
Adult | 11 | 2022 | 212470 | 0.050 |
Why?
|
Immunotherapy | 1 | 2016 | 4137 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2017 | 10802 | 0.050 |
Why?
|
Female | 13 | 2022 | 377934 | 0.050 |
Why?
|
Mice | 8 | 2020 | 81128 | 0.050 |
Why?
|
Young Adult | 6 | 2022 | 56249 | 0.050 |
Why?
|
Prognosis | 4 | 2021 | 29226 | 0.050 |
Why?
|
Pyrimidines | 1 | 2011 | 2974 | 0.040 |
Why?
|
Animals | 10 | 2020 | 170894 | 0.040 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2021 | 347 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2016 | 10376 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2020 | 804 | 0.040 |
Why?
|
Microtubule-Associated Proteins | 1 | 2022 | 1108 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2020 | 409 | 0.040 |
Why?
|
Binding Sites | 1 | 2006 | 6295 | 0.040 |
Why?
|
Oncogenes | 1 | 2022 | 1259 | 0.040 |
Why?
|
Gender Identity | 1 | 2021 | 567 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 59 | 0.040 |
Why?
|
Transaminases | 1 | 2016 | 212 | 0.040 |
Why?
|
Mutagenesis | 1 | 2020 | 1290 | 0.040 |
Why?
|
Retroelements | 1 | 2016 | 159 | 0.040 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2020 | 645 | 0.040 |
Why?
|
S-Adenosylmethionine | 1 | 2016 | 211 | 0.030 |
Why?
|
Molecular Conformation | 1 | 2016 | 564 | 0.030 |
Why?
|
Chromatin | 2 | 2016 | 2741 | 0.030 |
Why?
|
Documentation | 1 | 2021 | 871 | 0.030 |
Why?
|
Pancreatic Ducts | 1 | 2016 | 335 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2015 | 459 | 0.030 |
Why?
|
Ligands | 1 | 2021 | 3334 | 0.030 |
Why?
|
Cohort Studies | 3 | 2022 | 39891 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11336 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2016 | 469 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2006 | 14243 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 20086 | 0.030 |
Why?
|
Azepines | 1 | 2015 | 339 | 0.030 |
Why?
|
Cisplatin | 1 | 2019 | 1663 | 0.030 |
Why?
|
Glycine | 1 | 2016 | 699 | 0.030 |
Why?
|
Genome | 1 | 2021 | 1755 | 0.030 |
Why?
|
Immunoblotting | 1 | 2016 | 1792 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3714 | 0.030 |
Why?
|
Glycolysis | 1 | 2016 | 818 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2006 | 18738 | 0.030 |
Why?
|
Computer Simulation | 1 | 2006 | 6100 | 0.030 |
Why?
|
Receptors, Virus | 1 | 2016 | 659 | 0.030 |
Why?
|
Paclitaxel | 1 | 2019 | 1674 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2016 | 1097 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2161 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 4312 | 0.030 |
Why?
|
Drug Design | 1 | 2016 | 1107 | 0.020 |
Why?
|
Neoplasm Proteins | 2 | 2016 | 3778 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2020 | 9804 | 0.020 |
Why?
|
DNA Repair | 1 | 2020 | 2061 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2016 | 3249 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1056 | 0.020 |
Why?
|
DNA Damage | 1 | 2020 | 2470 | 0.020 |
Why?
|
Benzenesulfonates | 1 | 2010 | 174 | 0.020 |
Why?
|
Gene Silencing | 1 | 2016 | 1616 | 0.020 |
Why?
|
Triazoles | 1 | 2015 | 922 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2016 | 1377 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6777 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1916 | 0.020 |
Why?
|
Forkhead Transcription Factors | 1 | 2016 | 1623 | 0.020 |
Why?
|
Tongue Neoplasms | 1 | 2010 | 177 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2016 | 1723 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39302 | 0.020 |
Why?
|
Genes, Neoplasm | 1 | 2010 | 392 | 0.020 |
Why?
|
Mice, Nude | 1 | 2015 | 3830 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2019 | 18353 | 0.020 |
Why?
|
Niacinamide | 1 | 2010 | 435 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2016 | 2120 | 0.020 |
Why?
|
Phenylurea Compounds | 1 | 2010 | 553 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2016 | 6676 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2015 | 2511 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11200 | 0.020 |
Why?
|
Gene Dosage | 1 | 2010 | 1270 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2010 | 888 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2016 | 3933 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 13262 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2010 | 1320 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 7056 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 6051 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2016 | 3694 | 0.020 |
Why?
|
Pyrroles | 1 | 2010 | 1188 | 0.020 |
Why?
|
Gene Expression | 1 | 2016 | 8013 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 85143 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11777 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2015 | 4697 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16404 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2010 | 2593 | 0.010 |
Why?
|
Lung | 1 | 2020 | 9781 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9597 | 0.010 |
Why?
|
Pyridines | 1 | 2010 | 2871 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 22929 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 51277 | 0.010 |
Why?
|
Child | 1 | 2022 | 74388 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2020 | 72608 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2016 | 62344 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 34503 | 0.010 |
Why?
|